Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $3.75
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $4.5 to $3.75.
Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $4.5 to $3.75.